Jowell Go
3 Papers
Jowell Go is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.
Wassim Abida,David Campbell,Akash Patnaik,Alan H. Bryce,Jeremy Shapiro,Richard Martin Bambury,Jingdong Zhang,John M. Burke,Daniel Castellano,Albert Font,Vinod Ganju,Anne-Claire Hardy-Bessard,Ray McDermott,Brieuc Sautois,Dominique Spaeth,Eric Voog,Josep M. Piulats,Elias Pintus,Charles J. Ryan,Axel S. Merseburger,Gedske Daugaard,Axel Heidenreich,Karim Fizazi,Andrea Loehr,Darrin Despain,Andrew Simmons,Melanie Dowson,Jowell Go,Simon Paul Watkins,Simon Chowdhury +29 more
TL;DR: TRITON2 (NCT02952534) results demonstrated the efficacy of rucaparib 600 mg BID in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with a BRCA or other DNA damage repair (DDR) gene alteration as discussed by the authors .
42
TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
Wassim Abida,Alan H. Bryce,Arjun Vasant Balar,Gurkamal Chatta,Nancy A. Dawson,Elizabeth A. Guancial,Arif Hussain,Gautam Jha,David Uri Lipsitz,Akash Patnaik,Daniel P. Petrylak,Charles J. Ryan,Thomas S. Stanton,Nicholas J. Vogelzang,Jingsong Zhang,Andrew Simmons,Jowell Go,Tony Golsorkhi,Simon Chowdhury,Howard I. Scher +19 more
TL;DR: These data provide a compelling rationale for evaluating rucaparib, a potent PARP1, PARP2 and PARP3 inhibitor, in patients with mCRPC associated with HRD.
13
Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy.
Alan H. Bryce,Josep M. Piulats,M. Neil Reaume,Peter Ostler,Ray McDermott,Joel Roger Gingerich,Elias Pintus,Srikala S. Sridhar,Wassim Abida,Gedske Daugaard,Axel Heidenreich,Laurence Eliot Miles Krieger,Brieuc Sautois,Andrea Loehr,Darrin Despain,Jowell Go,Simon Paul Watkins,Simon Chowdhury,Charles J. Ryan,Karim Fizazi +19 more
TL;DR: The TRITON3 (NCT02975934) study as mentioned in this paper was a randomized, multicenter, open-label, phase 3 study of rucaparib vs physician's choice (docetaxel [DTX], abiraterone [ABI] or enzalutamide [ENZ]) in patients with chemotherapy-naïve mCRPC with BRCA1/2 (BRCA) or ATM alterations.